Evidence-based guidelines for venous thromboembolism prophylaxis in orthopedic surgery

Orthopedics

Volumn 30, Issue 2, 2007, Pages 129-135

  Colwell, Clifford W ^a,b  

^a SCRIPPS CLINIC   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMA PROTEIN; REVIPARIN; WARFARIN;

ANESTHESIOLOGICAL TECHNIQUES; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; ECHOGRAPHY; EVIDENCE BASED PRACTICE; HIP FRACTURE; HIP SURGERY; HUMAN; KNEE ARTHROSCOPY; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PARALYSIS; PATIENT SAFETY; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; SPINAL HEMATOMA; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 33947213267     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20070201-07     Document Type: Review

References (46)

1. Bick RL, Haas S. Thromboprophylaxis and thrombosis in medical, surgical, trauma, and obstetric/gynecologic patients. Hematol Oncol Clin North Am. 2003; 17:217-258.
2. Bhattacharyya T, Iorio R, Healy WL. Rate of and risk factors for acute inpatient mortality after orthopaedic surgery. J Bone Joint Surg Am. 2002; 84:562-572.
3. Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA. 1986; 256:744-749.
4. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988; 318:1162-1173.
5. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988; 208:227-240.
6. Agnelli G, Cosmi B, Di Filippo P, et al. A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost. 1992; 67:203-208.
7. Snook GA, Chrisman OD, Wilson TC. Thromboembolism after surgical treatment of hip fractures. Clin Orthop Relat Res. 1981; 153:21-24.
8. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001; 119(1 Suppl):132S-175S.
9. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest. 2003; 124(6 Suppl):386S-392S.
10. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 1994; 76:3-14.
11. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med. 2000; 160:2208-2215.
12. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997: 337:1329-1335.
13. Eriksson BI, Bauer KA, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Hip Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001; 345:1298-1304.
14. Lotke PA, Palevsky H, Keenan AM, et al. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Relat Res. 1996; 324:251-258.
15. Friedland DJ, ed. Evidence-based Medicine: a Framework for Clinical Practice. Stamford: Appleton & Lange; 1998.
16. Tapson VF. The evolution and impact of the American College of Chest Physicians consensus statement on antithrombotic therapy. Clin Chest Med. 2003; 24:139-151, vii.
17. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1986; 89(2 Suppl):2S-3S.
18. Guyatt G, Schunemann HJ, Cook D, Jaeschke R, Pauker S. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl):179S-187S.
19. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl):338S-400S.
20. Bauer KA, Eriksson BI, Lassen MR. Turpie AG; Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001; 345:1305-1310.
21. Lassen MR, Bauer KA, Eriksson BI, Turpie AG; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering. Post-operative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002; 359:1715-1720.
22. Turpie AG, Bauer KA, Eriksson BI, Lassen MR; PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002; 359:1721-1726.
23. Brott T, Stump D. Overview of hemostasis and thrombosis. Semin Neurol. 1991; 11:305-313.
24. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaecharide (fondaparinux). Thromb Res. 2003; 109:1-11.
25. Bauer KA. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. Chest. 2003; 124:364S-370S.
26. Stringer MD, Steadman CA, Hedges AR, Thomas EM, Morley TR, Kakkar VV. Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients. J Bone Joint Surg Br. 1989; 71:492-497.
27. Demers C, Marcoux S, Ginsberg JS, Laroche F, Cloutier R, Poulin J. Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med. 1998; 158:47-50.
28. Williams JS Jr, Hulstyn MJ, Fadale PD, et al. Incidence of deep vein thrombosis after arthroscopic knee surgery: a prospective study. Arthroscopy. 1995; 11:701-705.
29. Cullison TR, Muldoon MP, Gorman JD, Goff WB. The incidence of deep venous thrombosis in anterior cruciate ligament reconstruction. Arthroscopy. 1996; 12:657-659.
30. Jaureguito JW, Greenwald AE, Wilcox JF, Paulos LE, Rosenberg TD. The incidence of deep venous thrombosis after arthroscopic knee surgery. Am J Sports Med. 1999; 27:707-710.
31. Delis KT, Hunt N, Strachan RK, Nicolaides AN. Incidence, natural history and risk factors of deep vein thrombosis in elective knee arthroscopy. Thromb Haemost. 2001; 86:817-821.
32. Wirth T, Schneider B, Misselwitz F, et al. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial. Arthroscopy. 2001; 17:393-399.
33. Michot M, Conen D, Holtz D, et al. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low-molecular weight heparin. Arthroscopy. 2002; 18:257-263.
34. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998; 158:1525-1531.
35. Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med. 2002; 162:1465-1471.
36. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001; 83:336-345.
37. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355:1295-1302.
38. Eriksson BI, Lassen MR; Pentasaccharide in hip-fracture surgery plus investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003; 163:1337-1342.
39. Hull RD, Pineo GE, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001; 135:858-869.
40. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med. 2002; 162:1966-1971.
41. Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003; 124 (6 Suppl):379S-385S.
42. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Anesth Analg. 1997; 85:874-885.
43. Stratton MA, Anderson FA, Bussey HI, et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med. 2000; 160:334-340.
44. Stark JE, Kilzer WJ. Venous thromboembolic prophylaxis in hospitalized medical patients. Ann Pharmacother 2004; 38:36-40.
45. Audet AM, Anderson FA, St John R. The prevention of venous thromboembolism: a statewide evaluation of practices in Massachusetts. Therapie. 1998; 53:591-594.
46. Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr; Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest. 2003; 124(6 Suppl):349S-356S.